Abstract
The new quinolones are rarely indicated for the treatment of community-acquired pneumonia in the normal host. For nosocomial pneumonia they may be used when a Gram-negative aerobic bacillus is the causative organism. Pneumonia in the compromised host may be an indication for a quinolone. In the hypogammaglobulinaemic patient withHaemophilus influenzae pneumonia, the quinolones may be used, especially when the organism is resistant to other drugs. For the neutropenic patient with Gram-negative pneumonia the quinolones may be a good choice. However, more clinical studies are needed. In treatment for exacerbations of chronic bronchitis, failures seem to be associated with pneumococcal infections. For patients with cystic fibrosis, the quinolones offer successful ambulatory treatment for theirPseudomonas andHaemophilus infections. The information regarding dosage schedules is still incomplete.
Similar content being viewed by others
References
Meyer RD. Activity of quinolones againstLegionella. Quinol Bull 1988;2:13–4.
Garcia-Rodriguez JA. Activity of quinolones against mycobacteria (in vitro andin vivo). Quinol Bull 1988;4:21–5.
Maesen FPV, Davies BI, Teengs JP. Pefloxacin in acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1986;16:379–88.
Bosso JA, Black PG, Matsen JM. Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult patients with cystic fibrosis. Am J Med 1987;82 (Suppl 4A):180–4.
Hodson ME, Roberts CM, Butland RJA, Smith MJ, Batten JC. Oral ciprofloxacin compared with conventional intravenous treatment forPseudomonas aeruginosa infection in adults with cystic fibrosis. Lancet 1987;1:235.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
van der Meer, J.W.M. The place of quinolones in the treatment of respiratory tract infections. Pharmaceutisch Weekblad Scientific Edition 11, 132–133 (1989). https://doi.org/10.1007/BF01987958
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01987958